Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

QR Code

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication

Fu De Yang,1 Juan Li,1 Yun Long Tan,1 Wei Ye Liang,1 Rongzhen Zhang,1 Ning Wang,1 Wei Feng,1 Shangli Cai,2 Jian Min Zhuo,2 Li Li Zhang2 1Beijing Hui-Long-Guan Hospital, 2Department of Medical Affairs, Xian Janssen Pharmaceutical Ltd, Beijing, People’s Republic of China Objective: The aim...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yang FD, Li J, Tan YL, Liang WY, Zhang R, Wang N, Feng W, Cai S, Zhuo JM, Zhang LL
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2017
Sujets:	Paliperidone ER Schizophrenia Medical Satisfaction Questionnaire Chinese Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/4be20db0d4234dc9ab21b5594bf58fd8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
par: Jariyavilas A, et autres
Publié: (2017)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
par: Zhang LL, et autres
Publié: (2016)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
par: Si T, et autres
Publié: (2019)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
par: Mathews M, et autres
Publié: (2020)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
par: Shi C, et autres
Publié: (2016)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
par: Lambert M, et autres
Publié: (2020)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
par: Emsley R, et autres
Publié: (2018)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
par: Chen CY, et autres
Publié: (2018)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
par: Gattaz WF, et autres
Publié: (2020)

Engineering cocrystals of Paliperidone with enhanced solubility and dissolution characteristics
par: Radha-Rani Earle, et autres
Publié: (2021)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
par: Such P, et autres
Publié: (2021)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
par: Emsley R, et autres
Publié: (2017)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
par: Tzu-Pei Yeh, et autres
Publié: (2021)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
par: Mathews M, et autres
Publié: (2018)

Validation of a quick and simple chromatographic method for simultaneous quantification of sertraline, escitalopram, risperidone and paliperidone levels in the human plasma
par: Jeremić Aleksandra, et autres
Publié: (2021)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
par: Ibrahim Turkoz, et autres
Publié: (2008)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
par: Savitz AJ, et autres
Publié: (2017)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
par: Cuomo I, et autres
Publié: (2018)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
par: Di Lorenzo R, et autres
Publié: (2019)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
par: Cai SL, et autres
Publié: (2015)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
par: Li N, et autres
Publié: (2018)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
par: Zhi P, et autres
Publié: (2018)

c-Fos expression in the hypothalamic paraventricular nucleus after a single treatment with a typical haloperidol and nine atypical antipsychotics: a pilot study
par: Kiss Alexander
Publié: (2018)

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
par: Müller HHO, et autres
Publié: (2021)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
par: Leonid Mikhaylovich Bardenshteyn, et autres
Publié: (2010)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
par: Stephan Hjorth, et autres
Publié: (2021)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Role of paliperidone extended-release in treatment of schizoaffective disorder
par: Carla M Canuso, et autres
Publié: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
par: Marino J, et autres
Publié: (2012)

Antipsychotics and risk of natural death in patients with schizophrenia
par: Chen Y, et autres
Publié: (2019)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
par: Shao Q, et autres
Publié: (2015)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
par: Ping Yin, et autres
Publié: (2021)

Altered Peripheral Immune Profiles in First-Episode, Drug-Free Patients With Schizophrenia: Response to Antipsychotic Medications
par: Lei Chen, et autres
Publié: (2021)